US Edition
Bantam Pharmaceutical to Present at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
- On May 22, 2025, Bantam Pharmaceutical revealed that its ongoing early-stage clinical study of the investigational agent BTM-3566 for patients with relapsed or refractory mature B-cell lymphomas will be featured at the ASCO 2025 Annual Meeting in Chicago.
- The presentation follows Bantam's pursuit of novel therapies targeting mitochondrial dynamics to address unmet oncology needs in difficult-to-treat hematologic cancers.
- The multicenter, dose-escalation trial in the U.S. And Canada evaluates oral BTM-3566 activating the OMA1-ATF4 ISR pathway, focusing on safety, tolerability, and preliminary efficacy endpoints.
- Trial endpoints include safety and objective response rate by revised Lugano criteria, with initial clinical data expected in late 2025; Dr. Michael Wang will present the abstract TPS7097 on June 1.
- This presentation marks a significant clinical milestone as Bantam advances BTM-3566 to expand treatment options for patients facing limited therapies in aggressive B-cell lymphomas.
57 Articles
57 Articles
The Conway Daily Sun
Bantam Pharmaceutical to Present at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
RESEARCH TRIANGLE PARK, N.C., May 22, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that its Trial in Progress abstract has been accepted for presentation at the…
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - Biodesix (NASDAQ:BDSX)
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the IN…
Coverage Details
Bias Distribution
- 68% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
